

PATIENT INFORMATION				
Patient Name: _____ Patient SSN#: _____				
Address: _____ <small style="text-align: center;">Address, City, State, Zip Code</small>				
Phone #: _____ 2 nd Phone #: _____ Date of Birth: _____ Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female				
Weight (lbs): _____ Height (in.): _____ Allergies: _____				
MEDICATION	COMPOSITION	DIRECTIONS	QTY	REFILLS
<input type="checkbox"/> NALTREXONE 2 MG CAPSULE	Naltrexone 2mg PCCA Lactose or Sucrose	<input type="checkbox"/> Take 1 Capsule QD <input type="checkbox"/> Take 2 Capsules QD	<input type="checkbox"/> 30 <input type="checkbox"/> 60	
<input type="checkbox"/> NALTREXONE 4 MG CAPSULE	Naltrexone 4 mg PCCA Lactose or Sucrose	<input type="checkbox"/> Take 1 Capsule QD	<input type="checkbox"/> 30	
PHYSICIAN INFORMATION				
Physician Name: _____		Physician's Signature: _____ Date: _____		
NPI #: _____		<input type="checkbox"/> Dispense As Written Ship to: <input type="checkbox"/> Physician's Office <input type="checkbox"/> Patient's Home		
Address: _____		I AUTHORIZE DELTA DRUGS AND ITS REPRESENTATIVES TO ACT AS AN AGENT TO INITIATE AND EXECUTE THE INSURANCE PRIOR AUTHORIZATION PROCESS.		
Phone #: _____ Fax #: _____		I ALSO UNDERSTAND THAT THE FDA DOES NOT REVIEW ANY COMPOUNDED MEDICATION FOR SAFETY OR EFFICACY.		

PRIVACY NOTICE: This communication may contain non-public or legally privileged information intended for the sole use of the designated recipient(s). If you are not the intended recipient, or have received this communication in error, please notify the sender immediately via fax or by telephone at the number stated above and delete all copies of this communication, including any attachments, without reading or creating copies of them. If you are the intended recipient, you must secure the contents of this communication in accordance with all applicable state or federal requirements related to the privacy and security of information, including the HIPAA Privacy guidelines. © 2016 Delta Drugs All Rights Reserved

PATIENT INFORMATION				
Patient Name: _____ Patient SSN#: _____				
Address: _____ <small style="text-align: center;">Address, City, State, Zip Code</small>				
Phone #: _____ 2 nd Phone #: _____ Date of Birth: _____ Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female				
Weight (lbs): _____ Height (in.): _____ Allergies: _____				
MEDICATION	COMPOSITION	DIRECTIONS	QTY	REFILLS
<input type="checkbox"/> NALTREXONE 2 MG CAPSULE	Naltrexone 2mg PCCA Lactose or Sucrose	<input type="checkbox"/> Take 1 Capsule QD <input type="checkbox"/> Take 2 Capsules QD	<input type="checkbox"/> 30 <input type="checkbox"/> 60	
<input type="checkbox"/> NALTREXONE 4 MG CAPSULE	Naltrexone 4 mg PCCA Lactose or Sucrose	<input type="checkbox"/> Take 1 Capsule QD	<input type="checkbox"/> 30	
PHYSICIAN INFORMATION				
Physician Name: _____		Physician's Signature: _____ Date: _____		
NPI #: _____		<input type="checkbox"/> Dispense As Written Ship to: <input type="checkbox"/> Physician's Office <input type="checkbox"/> Patient's Home		
Address: _____		I AUTHORIZE DELTA DRUGS AND ITS REPRESENTATIVES TO ACT AS AN AGENT TO INITIATE AND EXECUTE THE INSURANCE PRIOR AUTHORIZATION PROCESS.		
Phone #: _____ Fax #: _____		I ALSO UNDERSTAND THAT THE FDA DOES NOT REVIEW ANY COMPOUNDED MEDICATION FOR SAFETY OR EFFICACY.		

PRIVACY NOTICE: This communication may contain non-public or legally privileged information intended for the sole use of the designated recipient(s). If you are not the intended recipient, or have received this communication in error, please notify the sender immediately via fax or by telephone at the number stated above and delete all copies of this communication, including any attachments, without reading or creating copies of them. If you are the intended recipient, you must secure the contents of this communication in accordance with all applicable state or federal requirements related to the privacy and security of information, including the HIPAA Privacy guidelines. © 2016 Delta Drugs All Rights Reserved

USES OF LOW DOSE NALTREXONE

CANCERS

- Bladder Cancer
- Breast Cancer
- Carcinoid
- Colon & Rectal Cancer
- Glioblastoma
- Liver Cancer
- Lung Cancer (Non-Small Cell)
- Lymphocytic Leukemia (chronic)
- Lymphoma (Hodgkin's and Non-Hodgkin's)
- Malignant Melanoma
- Multiple Myeloma
- Neuroblastoma
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer (untreated)
- Renal Cell Carcinoma
- Throat Cancer
- Uterine Cancer

OTHER DISEASES

- Common Colds (URI's)
- Emphysema (COPD)
- HIV/AIDS
- Depression (Major; and Bipolar)
- Lyme Disease (LATE Stage)

AUTOIMMUNE

NEURODEGENERATIVE:

- ALS (Lou Gehrig's Disease)
- Alzheimer's Disease
- Autism Spectrum Disorders
- Hereditary Spastic Paraparesis
- Multiple Sclerosis (MS)
- Parkinson's Disease
- Post-Polio Syndrome
- Post-Traumatic Stress Disorder (PTSD)
- Primary Lateral Sclerosis (PLS)
- Progressive Supranuclear Palsy

- Transverse Myelitis

OTHER AUTOIMMUNE DISEASES:

- Ankylosing Spondylitis
- Behcet's Disease
- Celiac Disease
- Chronic Fatigue Syndrome
- CREST syndrome
- Crohn's Disease
- Dermatomyositis
- Dystonia
- Endometriosis
- Fibromyalgia
- Hashimoto's Thyroiditis
- Irritable Bowel Syndrome (IBS)
- Myasthenia Gravis (MG)
- Nephrotic Syndrome
- Pemphigoid
- Primary Biliary Cirrhosis
- Psoriasis
- Rheumatoid Arthritis
- Sarcoidosis
- Scleroderma
- Sjogren's Syndrome
- Stiff Person Syndrome (SPS)
- Systemic Lupus (SLE)
- Ulcerative Colitis
- Wegener's Granulomatosis

LDN has demonstrated efficacy in thousands of cases.

Cancer. As of mid-2004, Dr. Bihari reported having treated over 300 patients who had a cancer that had failed to respond to standard treatments. Of that group, some 50%, after four to six months treatment with LDN, began to demonstrate a halt in cancer growth and, of those, over one-third have shown objective signs of tumor shrinkage.

Autoimmune diseases. Within the group of patients who presented with an autoimmune disease (see above list), none have failed to respond to LDN; all have experienced a halt in progression of their illness. In many patients there was a marked remission in signs and symptoms of the disease. The greatest number of patients within the autoimmune group are people with multiple sclerosis, of whom there were some 400 in Dr. Bihari's practice. Less than 1% of these patients has ever experienced a fresh attack of MS while they maintained their regular LDN nightly therapy.

HIV/AIDS. As of September 2003, Dr. Bihari had been treating 350 AIDS patients using LDN in conjunction with accepted AIDS therapies. Over the prior 7 years over 85% of these patients showed no detectable levels of the HIV virus — a much higher success rate than most current AIDS treatments, and with no significant side effects. It is also worth noting that many HIV/AIDS patients have been living symptom-free for years taking only LDN with no other medications.

Central Nervous System disorders. Anecdotal reports continue to be received concerning beneficial effects of LDN on the course of Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS—Lou Gehrig's disease), and primary lateral sclerosis. Dr. Jaquelyn McCandless has found a very positive effect of LDN, in appropriately reduced dosage and applied as a transdermal cream, in children with autism.

Information retrieved from:
www.lowdosenaltrexone.org

Arthritis & Rheumatism

Volume 65, Issue 2, pages 529–538, February 2013

Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counter-balanced, crossover trial assessing daily pain levels

Jarred Younger, Noorulain Noor, Rebecca McCue, Sean Mackey [Stanford University]

J Clin Gastroenterol. 2012 Nov 21. [Epub ahead of print]

Safety and Tolerability of Low-dose Naltrexone Therapy in Children With Moderate to Severe Crohn's Disease: A Pilot Study.

Smith JP, Field D, Bingaman SI, Evans R, Mauger DT.

Journal of AIDS and HIV Research
Vol. 3(10), pp. 180-188, October 2011

CLINICAL TRIALS FOR LDN

Single cohort study of the effect of low dose naltrexone on the evolution of immunological, virological and clinical state of HIV+ adults in Mali

Abdel K. TRAORE, Oumar THIERO, Sounkalo DAO, Fadia F. C. KOUNDE, Ousmane FAYE, Mamadou CISSE, Jaquelyn B. McCANDLESS, Jack M. ZIMMERMAN, Karim COULIBALY, Ayouba DIARRA, Mamadou S. KEITA, Souleymane DIALLO, Ibrahima G. TRAORE and Ousmane KOITA

Impact of low dose naltrexone (LDN) on antiretroviral therapy (ART) treated HIV+ adults in Mali: A single blind randomized clinical trial

Abdel K. TRAORE, Oumar THIERO, Sounkalo DAO, Fadia F. C. KOUNDE, Ousmane FAYE, Mamadou CISSE, Jaquelyn B. McCANDLESS, Jack M. ZIMMERMAN, Karim COULIBALY, Ayouba DIARRA, Mamadou S. KEITA, Souleymane DIALLO, Ibrahima G. TRAORE and Ousmane KOITA

Dig Dis Sci. 2011 Mar 8. [Epub ahead of print]

Therapy with the Opioid Antagonist Naltrexone Promotes Mucosal Healing in Active Crohn's Disease: A Randomized Placebo-Controlled Trial.

Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, Zagon IS.

Pilot trial of low dose naltrexone and quality of life in MS

Bruce A.C. Cree, Elena Korniyeva, Douglas S. Goodin
Multiple Sclerosis Center at UCSF

Multiple Sclerosis. 2008 Sep;14(8):1076-83.

A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis.

Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G.

PRICING TABLE

MEDICATION	QTY	PRICE
NALTREXONE 2 MG CAPSULES	30	\$30.00
	60	\$45.00
NALTREXONE 4 MG CAPSULES	30	\$45.00